Identifying the optimal cutoff point for MGMT promoter methylation status in glioblastoma.

CNS Oncol · 2021 · PMC8461752 · PMID 34486380

Europe PMC DOI

hedged sentence

0.0550

closest p · 1.1× alpha

0.0550

boldest claim

The sentences

did not reach statistical significancep = 0.055so close (0.05 < p ≤ 0.1)

They showed that the addition of TMZ had the greatest benefit in MGMT methylated patients (median OS 13.5 vs 7.7 months, HR: 0.53, CI: 0.38–0.73, p < 0.001), but the OS did not reach statistical significance in the MGMT unmethylated group (median OS 10 vs 7.9 months; HR: 0.75, CI: 0.56 to 1.01, p = 0.055, p = 0.08 for interaction) [ 25 ].

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.